PT  - JOURNAL ARTICLE
AU  - Li, Yun
AU  - Li, Moming
AU  - Rice, Megan
AU  - Su, Yanfang
AU  - Yang, Chaowei
TI  - Phased implementation of COVID-19 vaccination: rapid assessment of policy adoption, reach and effectiveness to protect the most vulnerable in the US
AID  - 10.1101/2021.02.19.21252118
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.19.21252118
4099  - http://medrxiv.org/content/early/2021/02/23/2021.02.19.21252118.short
4100  - http://medrxiv.org/content/early/2021/02/23/2021.02.19.21252118.full
AB  - Objectives The US and rest of the world have suffered from the COVID-19 pandemic for over a year. The high transmissibility and severity of this virus have provoked governments to adopt a variety of mitigation strategies. Some of these previous measures, such as social distancing and mask mandates, were effective in reducing the case growth rate yet became economically and administratively difficult to enforce as the pandemic continued. In late December 2020, COVID-19 vaccines were first approved in the US and states began a phased implementation of COVID-19 vaccination. However, there is limited quantitative evidence regarding the effectiveness of the phased COVID-19 vaccination. This study aims to provide a rapid assessment of the adoption, reach, and effectiveness of the phased implementation of COVID-19 vaccination.Methods We utilize an event-study analysis to evaluate the effect of vaccination on the state-level, daily COVID-19 case growth rate.Results Through this analysis, we assert that vaccination is effective in reducing the spread of COVID-19 shortly after the first shots were given. Specifically, the case growth rate declined by 0.124, 0.347, 0.345, 0.464, 0.490, and 0.756 percentage points corresponding to the 1-5, 6-10, 11-15, 16-20, 21-25, and 26 or more day periods after the initial shots.Conclusions The findings could be insightful for policymakers as they work to optimize vaccine distribution in later phases, and also for the public as the COVID-19 related health risk is a contentious issue.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by NSF 2027521, 1841520, and 1835507.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB is not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://github.com/stccenter/COVID-19-Data